Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis

David C Chen; Siyu Huang; Nathan Papa; Shankar Siva; Damien M Bolton; Nathan Lawrentschuk; Louise Emmett; Declan G Murphy; Michael S Hofman; Marlon L Perera

doi:10.1111/bju.16608

Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis

BJU Int. 2025 Jan 7. doi: 10.1111/bju.16608. Online ahead of print.

Authors

David C Chen^{1

2

3}, Siyu Huang¹, Nathan Papa⁴, Shankar Siva^{5

6}, Damien M Bolton^{3

6}, Nathan Lawrentschuk^{1

6

7

8}, Louise Emmett^{4

9

10}, Declan G Murphy^{1

6}, Michael S Hofman^{2

5}, Marlon L Perera^{1

3

6}

Affiliations

¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ Department of Urology, Austin Health, Melbourne, Victoria, Australia.
⁴ Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
⁵ Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁶ Sir Peter MacCallum Department of Oncology, Grattan Street University of Melbourne, Melbourne, Victoria, Australia.
⁷ EJ Whitten Prostate Cancer Research Centre, Epworth HealthCare, Melbourne, Victoria, Australia.
⁸ Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
⁹ Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.
¹⁰ St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

PMID: 39763428
DOI: 10.1111/bju.16608

Abstract

Objective: To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV_max) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).

Methods: Prostate-specific membrane antigen PET may offer non-invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV_max of the dominant lesion has been explored as a prognostic biomarker. Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we performed reviews of digital libraries and databases and retrieved studies reporting SUV_max quantified on PSMA PET computed tomography or magnetic resonance imaging and subsequent radical prostatectomy ISUP Grade Group, pT stage, and BCR. Quality assessment was performed using Quality Assessment of Diagnostic Accuracy Studies-2 and Prediction model Risk of Bias Assessment tools. Random effects meta-analysis and meta-regression by ISUP Grade Group and pT2 vs pT3/4 stage was performed. This study was registered on the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023408170).

Evidence synthesis: After removing duplicates, 23 studies were included for review. Pooled SUV_max (95% confidence interval [CI]) increased monotonically with advancing ISUP Grade Group, with ISUP 1: 5.8 (95% CI 3.9-7.7), through to ISUP 5: 17.3 (95% CI 13.1-21.5). For pT2 disease, pooled SUV_max: 9.7 (95% CI 7.8-11.5) increasing to 13.8 (95% CI 10.9-16.7) for pT3/4 disease. Substantial inconsistency was noted (I² >50%) for all subgroups. This was not attenuated by restricting analysis only to studies using [⁶⁸Ga]Ga-PSMA-11. Narrative synthesis of six papers reporting BCR showed increasing SUV_max was associated with reduced time to BCR.

Conclusion: Preoperative intraprostatic PSMA SUV_max increases monotonically with higher ISUP Grade Group and pathological tumour stage. Higher SUV_max is associated with reduced BCR-free survival. However, the use of single SUV_max thresholds for clinical decision making is not recommended as variability between studies is high.

Keywords: dominant intraprostatic lesion; maximum standardised uptake value; positron emission tomography; prostate‐specific membrane antigen; radical prostatectomy.

Publication types

Review